Table 3.
Total number of patients with diffuse large B-cell lymphoma, number with no rheumatology episodes, and number three or more rheumatology episodes distributed by prognostic factors and treatment: HMRN diagnoses 2009–2015, followed-up to 05/07/2018.
| All patients |
Treated with curative intent |
|||||
|---|---|---|---|---|---|---|
| Rheumatology episodes |
Rheumatology episodes |
|||||
| N (%) | None (%) | 3 or more (%) | N (%) | None (%) | 3 or more (%) | |
| Total | 1771(100.0) | 1597(100.0) | 111(100.0) | 1421(100.0) | 1294(100.0) | 81(100.0) |
| Age, median (IQR) | 70.6 (61.1–79.1) |
70.3 (60.7–78.9) |
73.0 (66.3–79.7) |
68.3 (59.5–76.6) |
68.0 (58.9–76.3) |
71.1 (65.8–78.3) |
| Z=−3.01, p < 0.01 | Z=−3.05, p < 0.01 | |||||
| Performance status | ||||||
| 0- Good | 567(32.0) | 537(33.6) | 19(17.1) | 549(38.6) | 520(40.2) | 19(23.5) |
| 1 | 583(32.9) | 527(33.0) | 36(32.4) | 522(36.7) | 469(36.2) | 33(40.7) |
| 2 | 356(20.1) | 309(19.3) | 33(29.7) | 250(17.6) | 218(16.8) | 20(24.7) |
| 3 & 4- Poor | 205(11.6) | 170(10.6) | 19(17.1) | 86(6.1) | 75(5.8) | 7(8.6) |
| χ2 = 18.2, p < 0.01 | χ2 = 9.72, p = 0.02 | |||||
| B symptoms | ||||||
| Absent | 1002(56.6) | 917(57.4) | 50(45.0) | 819(57.6) | 754(58.3) | 43(53.1) |
| Present | 739(41.7) | 652(40.8) | 60(54.1) | 602(42.4) | 540(41.7) | 38(46.9) |
| χ2 = 7.10, p < 0.01 | χ2 = 0.84, p = 0.36 | |||||
| Cancer stage | ||||||
| I & II | 497(28.1) | 454(28.4) | 28(25.2) | 469(33.0) | 430(33.2) | 25(30.9) |
| III & IV | 925(52.2) | 829(51.9) | 59(53.2) | 766(53.9) | 689(53.2) | 50(61.7) |
| Not Fully Staged | 319(18.0) | 286(17.9) | 23(20.7) | 186(13.1) | 175(13.5) | 6(7.4) |
| χ2 = 0.85, p = 0.65 | χ2 = 3.32, p = 0.19 | |||||
| 3-year OS (95% CI) |
57.4 (55.1–59.7) |
58.5 (56.0–60.8) |
46.6 (37.0–55.6) |
68.2 (65.7–70.6) |
68.6 (66.0–71.1) |
62.6 (51.0–72.2) |
| χ2 = 6.77, p < 0.01 | χ2 = 1.12, p = 0.29 | |||||
| Fully adjusted HR1(95%CI) | 1(ref) | 1.0(0.8–1.3) | 1(ref) | 0.9(0.6–1.3) | ||
1
Hazard ratios adjusted for age, performance status, B symptoms, and stage.